Clinical Trial

Study of Alpha Radioligand Therapy AB001 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

Study acronym: ARTISAN
Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This Phase 1 study will evaluate the safety, tolerability, and preliminary effectiveness of AB001, an alpha-emitting radioligand targeting prostate-specific membrane antigen (PSMA), in patients with advanced prostate cancer who are either 177Lu-PSMA naïve or experienced. The study includes dose escalation to identify a recommended dose and dose expansion to further assess safety and anti-tumour activity. Primary objectives are to characterize the safety profile and determine the optimal dose and schedule for future studies
Protocol Amendment History 1 change
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-04-08
Trial Details
NCT Number NCT07214961
Lead Sponsor ARTBIO Inc.
Conditions Prostate Cancer (CRPC), Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Enrollment 80 participants
Start Date 2025-11-03
Primary Completion 2027-11-03 (estimated)
Study Completion 2028-11-03 (estimated)
Updated on ClinicalTrials.gov 2026-04-07